EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
2011

EGFR Gene Amplification in Cervical Cancer

Sample size: 111 publication Evidence: moderate

Author Information

Author(s): Iida K, Nakayama K, Rahman M T, Rahman M, Ishikawa M, Katagiri A, Yeasmin S, Otsuki Y, Kobayashi H, Nakayama S, Miyazaki K

Primary Institution: Shimane University School of Medicine

Hypothesis

The study investigates the relationship between EGFR gene amplification and clinical outcomes in cervical squamous cell carcinoma.

Conclusion

EGFR gene amplification is associated with shorter overall survival in cervical squamous cell carcinoma patients.

Supporting Evidence

  • 10.2% of cervical squamous cell carcinomas showed significant amplification of the EGFR locus.
  • EGFR amplification significantly correlated with shorter overall survival.
  • EGFR gene amplification was an independent prognostic factor for overall survival.

Takeaway

This study found that some cervical cancer cells have extra copies of a gene called EGFR, which can make the cancer worse.

Methodology

The study used immunohistochemistry, fluorescence in situ hybridization, and PCR to assess EGFR expression, amplification, and mutations in cervical carcinomas.

Potential Biases

Differences in methodological protocols may introduce variability in results.

Limitations

The study's sample size is relatively small, which may affect the reliability of the results.

Participant Demographics

Median patient age was 60 years for squamous cell carcinoma and 46 years for adenocarcinoma/adenosquamous carcinoma.

Statistical Information

P-Value

0.001

Confidence Interval

95% CI not provided

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/bjc.2011.222

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication